Get started

NVS

Novartis | NVS | Long at $99.00As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is nearing the historical simple moving average line and may be poised for another move up. However, entry into the lower $90's or even $80's is still not off the table and, in my view, a great opportunity. Thus, at $99.00, NYSE:NVS is in a personal buy zone. Target #1 = $110.00 Target #2 = $120.00
NYSE:NVSLong
by WorthlessViews
NVS 1H Swing Long Conservative Trend TradeConservative Trend Trade + long impulse + 1/2 correction + T2 level + support level - biggest volume 2Sp- Calculated affordable stop limit 1 to 2 R/R within 1H range take profit Daily Trend "+ long impulse + 1/2 correction + JOC level + support level - above 1/2 of entire 1D wave at the support level of 1M" Monthly Trend "+ long impulse + 1/2 correction + support level + JOC level - unvolumed manipulation" Yearly Trend "+ long impulse - resistance level + less than a month left and it looks to break + long volume distribution" NVS @NYSE Bought NVS Market, Day Filled 8:27 AM 104.89325 Profit Taker Sell NVS Limit 105.87, GTC Submitted 8:27 AM
NYSE:NVS
by MishaSuvorov
Novartis Strikes $1.01 Bln Deal with Arvinas for Prostate DrugsNovartis ( NYSE:NVS ), the Swiss pharmaceutical giant, has made a strategic move in the field of cancer treatment by securing a licensing agreement with Arvinas, a U.S. biotech company. The deal, valued at up to $1.01 billion, grants Novartis access to Arvinas' experimental prostate cancer drug, ARV-766. This collaboration marks Novartis' ( NYSE:NVS ) continued commitment to advancing cancer therapies, following its recent tender offer to acquire German cancer drugmaker MorphoSys for $2.9 billion. With a focus on fewer therapeutic areas and geographic markets, Novartis aims to bolster its oncology portfolio with innovative treatments. The agreement entails Novartis ( NYSE:NVS ) acquiring global rights to develop and commercialize ARV-766, making an initial payment of $150 million to Arvinas. Additionally, Novartis will acquire another preclinical-stage candidate, AR-V7, targeting prostate cancer, as part of the deal. ARV-766 represents a promising approach to combat prostate cancer by targeting and degrading androgen receptors, critical components in the progression of the disease. Arvinas' protein degradation platform, upon which ARV-766 is based, has garnered validation through this partnership, according to Truist Securities analyst Srikripa Devarakonda. In addition to the upfront payment, Arvinas stands to receive tiered royalties on sales of the drug, as well as potential milestone payments totaling up to $1.01 billion. This signifies a significant endorsement of Arvinas' innovative approach to developing treatments that leverage the body's natural protein disposal system to eliminate disease-causing proteins. Novartis' ( NYSE:NVS ) collaboration with Arvinas underscores the pharmaceutical industry's ongoing pursuit of novel therapeutic modalities to address unmet medical needs. By harnessing cutting-edge technologies and strategic partnerships, companies like Novartis and Arvinas are driving innovation in the fight against cancer, offering hope to patients worldwide.
NYSE:NVS
by DEXWireNews
Bullish on Novartis. NVSImmediate targets 94, 95. Invalidation 79. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NYSE:NVSLong
by Rykin_Capital
Calling bullish on Novartis. NVSLooks like we have a an end to a zigzag here. Technically, we have not left FibChannel, hence the approach is risky. If the picture is right, we may see one or more impulses upwards. Wait and see. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NYSE:NVSLong
by Rykin_Capital
Post 10/26 Q3 FY21’ Earnings Analysis$MMM, $AMP, $GOOGL, $GE, $AMD, $COF, $HAS, $V, $TWTR, $UPS, $RTX, $NVS $MMM - 3M - reported EPS of $2,45/share - beat estimates of $2.21/share - revenue of $8.94B +7.09% YoY Organic local-currency sales up 6.3% YoY Operating CF of $1.9B Adjusted FCF of $1.5B (20%) YoY Returned $1.4B to shareholders in dividends Industrial FCF tops estimates Narrows FY21 EPS outlook - trims full-year earnings view on supply chain challenges Down (0.09%) after hours $GOOGL - Google Alphabet Class A - reported EPS of $27.26/share - beat estimates of $19.89/share Revenue of $53.62B Top Line growth of 44% Ad Revenue of $53.13B up 44% Revenue from Cloud Division of $4.99B up 45% Reported a $188M gain on investments up 623.1% YoY Down (0.22%) after hours $GE - General Electric - reported EPS of $0.57/share - beat estimates of $0.24/share - revenue of $18.43B down (0.5%) YoY Improvements in FCF performance & growth in earnings - despite weakness in revenues Bottom Line up 50% YoY Sales suffered from weakness in Healthcare & Renewable Energy segments - partially offset by gains in Aviation Organic & Industrial Revenues down (1%) YoY - Aviation Revenues up 10% YoY Up +0.01% after hours $AMD - Advanced Micro Devices - reported EPS of $0.73/share - beat estimates of $0.67/share - revenue of $4.31B up 54% YoY Adjusted Gross Margin of 48% - in line with estimates - up 44% YoY Capital Expenditures of $85M Computer/Graphics segment revenue of $2.4B up 44% YoY Q4 revenue estimates raised to $4.6B Down (0.41%) after hours $COF - Capital One - Reported EPS of $4686/share - beat estimates of $4.99/share - revenue of $7.83B +6.1% YoY Earnings Surprise of 31.42% Beat consensus EPS estimates past 4 quarters Revenue rise reflects loan growth Net credit card charge-offs improved in Sept Down (4.01%) after hours $HAS - Hasbro - reported EPS of $1.96/share - beat estimates of $1.70/share - revenue of $1.97B +10.88% YoY Operating Profit of $367.9M up 9% YoY Adjusted Operating Profit of $389.6M up 6% YoY Net Earnings of $253.2M up 15% YoY Adjusted Net Earnings of $271.2M up 5% YoY Supply chain challenges weigh on top line Further reduced debt & maintained a strong cash position - repaid $400M of debt & funded quarterly dividend Up +1.46% after hours $V - Visa - reported EPS of $1.62/share - beat estimates of $1.53/share - revenue of $6.56B up 27.45% YoY Earnings Surprise of 5.88% Surpassed consensus EPS estimates past 4 quarters Announce boost in quarterly dividend Down (2.60%) after hours $TWTR - Twitter - reported EPS of ($0.54) - missing estimates of $0.02/share - revenue of $1.28B up 37% YoY Reported a net loss of ($537M) vs. $29M in FY20' due to a legal settlement - does not expect to recoup the full revenue loss Ad Revenue rose more than 41% YoY to $4.14B up 6% YoY Number of Monetized users grew by 5M - user base up 13% YoY Apple's privacy changes to iOS 14 has less of an impact than expected $UPS - United Parcel Service - reported EPS of $2.71/share - beat estimates of $2.55/share - revenue of $23.18B US Domestic Package Revenues of $14.2B up 7.4% YoY Bottom Line up 18.9% YoY with strong performance across all segments Top Line up 9.2% YoY drive by up beat demand for e-commerce related package deliveries Operating Profit of $2.97B up 23.4% YoY Up +0.52% after hours $RTX - Raytheon Technologies - reported EPS of $1.26/share - beating estimates of $1.08/share - revenue of $16.2B up 7.7% YoY Sales of $16.2B - missing estimates of $16.9B - up 9.9% YoY Operating Profit of $1.3B - up 209.5% YoY Bottom Line up 125% YoY - attributable to higher YoY revenues & operating profit Newly disclosed quarterly dividend paid $0.51/share on 10/19/21 - represents a $2.04 dividend on an annualized basis Down (0.46%) after hours $NVS - Novartis - reported EPS of $1.71/share - beat estimates of $1.64/share - revenue of $13.03B up 6.2% YoY Net Income of $2.76B up 43% YoY Net Sales $13,03B up 6% YoY - volume contributed 9 percentage points to sales growth Down (1.38%) after hours
SP:SPX
by jnallain1
Should re-test $98 in 2021NVS is a long term reliable dividend paying hold, but I try to be careful with pharmas. A lot of possible catalysts that can change the direction too soon. This is purely a trend line analysis. I see good indicators from trend lines in play and looks like the stock will re test the $98 high again before either a move up or down. I expect it to break downward by 2022. Caution: slow moving stock. It won't bleed your portfolio on red days, but watching paint dry would be a lot quicker than watching NVS go up a few percentage. Good luck!
NYSE:NVSLong
by Karam08
NVS (NYSE) - Go DownGreetings Humbled, we would like to thanks for your support who has already liked, commented and followed us. Your support, strengthens us, to help in analyzing the market. If you have any questions, feel free to send us message (inbox). Pra Trading : - Please care for Money Management - Have a good psychology - Do not be hurry to open position and do not do nothing if u see opportunity - Evaluate and upgrade your trading plan Execution Strategy : - Know what you want to buy, see the Fundamental - Decide that you are on investing or speculating - Consider what your strategy based on Investing/Speculating - Make Road Map Of Your Trading Plan - Decide a. Entry strategy b. Cut loss c. Target of Profit Post Trading : a. Do not be sad if you loss or do not be very happy if you win b. Just become a normal without emotion, Do not put emotion into your trading c. Evaluate your trading d. Keep on Learning e. Be Humble Idea : NVS (NYSE) - Go Down
NYSE:NVS
by MultiAssetX
Novartis: Buy opportunity with split entry.NVS was among the high cap losers yesterday on the renewed coronavirus tensions and pulled back dramatically (-6.90%). This however can be the buy opportunity of the next several months as it hit the 1D MA200 (orange line) and is approaching the Higher Low trend line of the 1W Channel Up (RSI = 45.378, MACD = 1.640, ADX = 65.865). Even though the MACD indicated the possibility of a deeper pull to the 84.00 1W Support before a meaningful rebound, we give equal probabilities for the rebound to start within the Higher Low zone. Our Target zone is 98.00 - 100.00. ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
NYSE:NVSLong
by InvestingScope
$MDCO Breaks Out, Expect Further Gains$MDCO has been having a banner year with the stock up over 200%. We think this rally still has legs and that $MDCO is going to keep climbing after Monday's huge breakout. Here's a look at what drove Monday's breakout. Results from a Phase 3 clinical trial, ORION-9, evaluating the effect of The Medicines Company's (MDCO +2.3%) inclisiran on reducing "bad" cholesterol (LDL-C) in patients with familial hypercholesterolemia (FH), an inherited condition characterized by abnormally high levels of cholesterol in the blood, showed a treatment benefit. The data were presented at the American Heart Association Scientific Sessions in Philadelphia. The study met the primary endpoints of percent change in LDL-C from baseline to day 510 (50% reduction) versus placebo and time-averaged percent change (45% reduction) in LDL-C after day 90 up to day 510 versus control. Both values were statistically significant. No new safety signals were observed. The results will be submitted for presentation in a peer-reviewed medical journal. The company expects to file a U.S. marketing application this quarter and one in Europe next quarter. The company will host a conference call today at 12 noon ET to discuss the results from ORION-9 and ORION-10. In other news, there are also rumblings this morning that Novartis (NYSE:NVS) may be circling. As always, use protective stops and trade with caution. Good luck to all!
MLong
by InsiderFinancial
Novartis almost a buyPharmaceutical stocks represents a defensive asset when a positive market cycle is about to finish or when it is foreseen a cycle less positive than the previous one. In such context pharma stocks should have an advantage because of inelastic demand for such goods. Novartis ($NVS,$NOVN) is one of the candidate to break up as the price is moving in a triangle since 2015. the stock doesn't not have an high volatility as other stocks but is one of the main represented of INDEX STOCK HEALTH CARE. There are nice technical indications on the chart that a breakout might happen in the next weeks. At the moment I am expecting a price pullback, where at the end it will be possible to go for an entry long. Conclusions At the moment price is consolidating and some other days to reduce RSI value will be needed. It's possible either to open positions at the end of the pullback or when price breaks out the downtrend (2015). Possibility to have it in CHF or $.
SIX:NOVN
by TRADOMICS_